Innovation Pharmaceuticals Inc (IPIX)

[TOB]

Sometimes it helps to actually read the article before drawing conclusions from a title.

I can't read the whole article but thanks for the Debby Downer if the Headlines sums up the rest of the article -eventhelosers

The article answers the question in the negative, basically, no, the Medicines company did not trump Cellceutix. Anyone can make a free registration and read the full article. I would encourage this as it is well written and clearly shows that Brilacidin is the leader.

Orbactiv is basically a generic vancomycin, and was compared with vancomycin. Another lipoglycopeptide like vancomycin and Dalvance. It has issues with side effects and will experience antibiotic resistance.

It will be used, but not a likely blockbuster. It is expected that U.S. sales of Orbactiv could reach $150 million by 2021. That is ho hum compared with the potential Blockbuster Brilacidin.

CTIX Brilacidin is a new class of antibiotics. Brilacidin was compared with the superior drug Daptomycin/Cubisin. Brilacidin has superior efficacy comparable to Daptomycin, not Vancomycin. Brilacidin has a better safety profile with a shorter half life, spending less time in the human body. Brilacidin is unlikely to develop antibiotic resistance, and indications are that it will be effective against a broader range of bacteria. Even inflammatory disease such as the soon to start trial for Oral Mucositis.

If Brilacidin results hold up in P3 Clinical Trials, it is a blockbuster. Orbactive is just a reformulated vancomycin with far less potential.